ES2272203T1 - DIFENIL-UREAS REPLACED IN OMEGA POSITION WITH CARBOXIARILO AS INHIBITORS OF THE RAF QUINASA. - Google Patents

DIFENIL-UREAS REPLACED IN OMEGA POSITION WITH CARBOXIARILO AS INHIBITORS OF THE RAF QUINASA. Download PDF

Info

Publication number
ES2272203T1
ES2272203T1 ES05028442T ES05028442T ES2272203T1 ES 2272203 T1 ES2272203 T1 ES 2272203T1 ES 05028442 T ES05028442 T ES 05028442T ES 05028442 T ES05028442 T ES 05028442T ES 2272203 T1 ES2272203 T1 ES 2272203T1
Authority
ES
Spain
Prior art keywords
substituted
phenyl
group
acid
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES05028442T
Other languages
Spanish (es)
Other versions
ES2272203T3 (en
Inventor
Bernd Riedl
Jacques Dumas
Uday Khire
Timothy B. Lowinger
William J. Scott
Roger A. Smith
Jill E. Wood
Mary-Katherine Monahan
Reina Natero
Joel Renick
Robert N. Sibley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2272203(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ES2272203T1 publication Critical patent/ES2272203T1/en
Application granted granted Critical
Publication of ES2272203T3 publication Critical patent/ES2272203T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de Fórmula I: A - D - B (I) o una sal farmacéuticamente aceptable del mismo, en la cual D es -NH-C(O)-NH-, A es un resto sustituido de hasta 40 átomos de carbono de la fórmula: -L-(M-L 1 )q, donde L es una estructura cíclica de 5 ó 6 miembros unida directamente a D, L1 comprende un resto cíclico sustituido que tiene al menos 5 miembros, M es un grupo formador de puentes que tiene al menos un átomo, q es un número entero de 1 a 3; y cada estructura cíclica de L y L1 contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre, y B es un resto arilo o heteroarilo sustituido o insustituido, hasta tricíclico que tiene hasta 30 átomos de carbono con al menos una estructura cíclica de 6 miembros unida directamente a D que contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre, en donde L1 está sustituido con al menos un sustituyente seleccionado del grupo constituido por -SO2Rx, -C(O)Rx y -C(NRy)Rz, Ry es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y opcionalmente halosustituido, hasta per-halo, Rz es hidrógeno o un resto basado en carbono de hasta de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.A compound of Formula I: A-D-B (I) or a pharmaceutically acceptable salt thereof, in which D is -NH-C (O) -NH-, A is a substituted moiety of up to 40 carbon atoms of the formula: -L- (ML 1) q, where L is a 5 or 6-member cyclic structure attached directly to D, L1 comprises a substituted cyclic moiety having at least 5 members, M is a bridge forming group having at least one atom, q is an integer from 1 to 3; and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and B is a substituted or unsubstituted aryl or heteroaryl moiety, up to tricyclic having up to 30 carbon atoms with at least one cyclic structure 6-member directly linked to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, where L1 is substituted with at least one substituent selected from the group consisting of -SO2Rx, -C (O) Rx and -C (NRy) Rz, Ry is hydrogen or a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, until per-halo, Rz is hydrogen or a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, containing option Highly heteroatoms selected from N, S and O and are optionally substituted with halogen.

Claims (67)

1. Un compuesto de Fórmula I:1. A compound of Formula I: (I)A - D - B(I) A - D - B o una sal farmacéuticamente aceptable del mismo, en la cualor a pharmaceutically salt acceptable of it, in the which D es -NH-C(O)-NH-,D is -NH-C (O) -NH-, A es un resto sustituido de hasta 40 átomos de carbono de la fórmula: -L-(M-L^{1})_{q}, donde L es una estructura cíclica de 5 ó 6 miembros unida directamente a D, L^{1} comprende un resto cíclico sustituido que tiene al menos 5 miembros, M es un grupo formador de puentes que tiene al menos un átomo, q es un número entero de 1 a 3; y cada estructura cíclica de L y L^{1} contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre, yA is a substituted residue of up to 40 atoms of carbon of the formula: -L- (M-L 1) q, where L is a cyclic structure of 5 or 6 members joined directly to D, L1 comprises a substituted cyclic moiety that It has at least 5 members, M is a bridge forming group that it has at least one atom, q is an integer from 1 to 3; and every cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, Y B es un resto arilo o heteroarilo sustituido o insustituido, hasta tricíclico que tiene hasta 30 átomos de carbono con al menos una estructura cíclica de 6 miembros unida directamente a D que contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre,B is a substituted aryl or heteroaryl moiety or unsubstituted, up to tricyclic having up to 30 carbon atoms with at least a 6-member cyclic structure directly attached a D containing 0-4 members of the constituted group by nitrogen, oxygen and sulfur, en donde L^{1} está sustituido con al menos un sustituyente seleccionado del grupo constituido por -SO_{2}R_{x}, -C(O)R_{x} y -C(NR_{y})R_{z},wherein L 1 is substituted with at least one substituent selected from the group consisting of -SO_ {2} R_ {x}, -C (O) R_ {x} y -C (NR_ {y}) R_ {z}, R_{y} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y opcionalmente halosustituido, hasta per-halo,R y is hydrogen or a residue based on carbon of up to 24 carbon atoms that optionally contains heteroatoms selected from N, S and O and optionally has replaced, even per-halo, R_{z} es hidrógeno o un resto basado en carbono de hasta de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;R_Z is hydrogen or a residue based on carbon up to 30 carbon atoms it contains optionally heteroatoms selected from N, S and O and substituted optionally with halogen, hydroxy and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen; R_{x} es R_{z} o NR_{a}R_{b}, donde R_{a} y R_{b} sonR_ {x} is R_ {z} or NR_ {a} R_ {b}, where R_ {a} and R_ {b} are a) independientemente hidrógeno,a) independently hydrogen, un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno, oa carbon-based moiety of up to 30 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen, or -OSi(R_{f})_{3} donde R_{f} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno; o-OSi (R_ {f}) 3 where R_ {f} is hydrogen or a carbon based moiety of up to 24 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen; or b) R_{a} y R_{b} forman juntos una estructura heterocíclica de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O sustituidos con halógeno, hidroxi o sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;
ob) R_a and Rb together form a 5-7 membered heterocyclic structure with 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic structure with 1-3 selected heteroatoms of N, S and O substituted with halogen, hydroxy or carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen;
or c) uno de R_{a} o R_{b} es -C(O)-, un grupo alquileno bivalente C_{1}-C_{5} o un grupo alquileno bivalente C_{1}-C_{5} unido al resto L para formar una estructura cíclica con al menos 5 miembros, en la cual los sustituyentes del grupo alquileno bivalente C_{1}-C_{5} sustituido se seleccionan del grupo constituido por halógeno, hidroxi, y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;c) one of R_ {a} or R_ {b} is -C (O) -, a C 1 -C 5 bivalent alkylene group or a group C 1 -C 5 bivalent alkylene attached to the rest L to form a cyclic structure with at least 5 members, in the which substituents of the bivalent alkylene group C_ {1} -C_ {5} substituted are selected from the group consisting of halogen, hydroxy, and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen; donde B está sustituido, L está sustituido o L^{1} está sustituido adicionalmente, los sustituyentes se seleccionan del grupo constituido por halógeno, hasta per-halo, y W_{n}, donde n es 0-3;where B is substituted, L is substituted or L1 is further substituted, the substituents are select from the group consisting of halogen, up to per-halo, and W_ {n}, where n is 0-3; en donde cada W se selecciona independientemente del grupo constituido por -CN, -CO_{2}R_{7}, -C(O)NR^{7}R^{7}, -C(O)-R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, -Q-Ar, y restos basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NO_{2}, -NR^{7}C(O)R^{7}, -NR^{7}C(O)OR^{7} y halógeno hasta per-halo; estando cada R^{7} seleccionado independientemente de H o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y sustituido opcionalmente con halógeno,where each W is independently selected of the group consisting of -CN, -CO 2 R 7, -C (O) NR 7 R 7, -C (O) -R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, -Q-Ar, and residues carbon based up to 24 carbon atoms, containing optionally heteroatoms selected from N, S and O and are optionally substituted with one or more selected substituents regardless of the group consisting of -CN, -CO2R7, -C (O) R 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NR 7 R 7, -NO 2, -NR 7 C (O) R 7, -NR 7 C (O) OR 7 and halogen up to per-halo; each R 7 being selected regardless of H or a carbon-based moiety of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and optionally substituted with halogen, en donde Q es -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, y X^{a} es halógeno; ywhere Q is -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, and X a is halogen; Y Ar es una estructura aromática de 5 ó 6 miembros que contiene 0-2 miembros seleccionados del grupo constituido por nitrógeno, oxígeno y azufre, que está sustituida opcionalmente con halógeno, hasta per-halo, y sustituida opcionalmente con Z_{n1}, en donde n1 es 0 a 3 y cada Z se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, y un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con uno o más sustituyentes seleccionados del grupo constituido por -CN, -CO_{2}R^{7}, -COR^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NO_{2}, -NR^{7}R^{7}-, -NR^{7}C(O)R^{7}, y -R^{7}C(O)OR^{7}, siendo R^{7} como se ha definido arriba.Ar is an aromatic structure of 5 or 6 members containing 0-2 selected group members consisting of nitrogen, oxygen and sulfur, which is substituted optionally with halogen, up to per-halo, and optionally substituted with Z_ {n1}, where n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO 2 R 7, -C (O) R 7, -C (O) NR 7 R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and is optionally substituted with one or more substituents selected from the group consisting of -CN, -CO 2 R 7, -COR 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NO 2, -NR 7 R 7 -, -NR 7 C (O) R 7, and -R 7 C (O) OR 7, where R 7 is as has been defined above. 2. Un compuesto de acuerdo con la reivindicación 1, en donde:2. A compound according to claim 1, where: R_{y} es hidrógeno, alquilo C_{1-10}, alcoxi C_{1-10}, cicloalquilo C_{3-10} que tiene 0-3 heteroátomos, alquenilo C_{2-10}, alquenoílo C_{1-10}, arilo C_{6-12}, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, aralquilo C_{7-24}, alcarilo C_{7-24}, alquilo C_{1-10} sustituido, alcoxi C_{1-10} sustituido, cicloalquilo C_{3-10} sustituido que tiene 0-3 heteroátomos seleccionados de N, S y O, arilo C_{6}-C_{14} sustituido, hetarilo C_{3-12} sustituido que tiene 1-3 heteroátomos seleccionados de N, S y O, alcarilo C_{7-24} sustituido o aralquilo C_{7-24} sustituido, y donde R_{y} es un grupo sustituido, el mismo está sustituido con halógeno hasta per-halo,R y is hydrogen, alkyl C 1-10, C 1-10 alkoxy, C 3-10 cycloalkyl having 0-3 heteroatoms, alkenyl C 2-10, C 1-10 alkenoyl, C 6-12 aryl, heteroaryl C_ {3-12} which has 1-3 heteroatoms selected from N, S and O, aralkyl C 7-24, C 7-24 alkaryl, C 1-10 substituted alkyl, alkoxy C 1-10 substituted, cycloalkyl C_ {3-10} substituted that has 0-3 heteroatoms selected from N, S and O, aryl C 6 -C 14 substituted, heteroaryl C_ {3-12} substituted that has 1-3 heteroatoms selected from N, S and O, alkaryl C 7-24 substituted or aralkyl C_ {7-24} substituted, and where R_ {y} is a group substituted, it is substituted with halogen until per-halo, R_{z} es hidrógeno, alquilo C_{1-10}, alcoxi C_{1-10}, cicloalquilo C_{3-10} que tiene 0-3 heteroátomos, alquenilo C_{2-10}, alquenoílo C_{1-10}, arilo C_{6-12}, hetarilo C_{3}-C_{12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcarilo C_{7-24}, aralquilo C_{7-24}, alquilo C_{1-10} sustituido, alcoxi C_{1-10} sustituido, arilo C_{6}-C_{14} sustituido, cicloalquilo C_{3}-C_{10} sustituido que tiene 0-3 heteroátomos seleccionados de S, N y O, hetarilo C_{3-12} sustituido que tiene 1-3 heteroátomos seleccionados de S, N y O, alcarilo C_{7-24} sustituido o aralquilo C_{7-24} sustituido, y donde R_{z} es un grupo sustituido, el mismo está sustituido con halógeno hasta per-halo, hidroxi, alquilo C_{1-10}, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados de O, S y N, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcoxi C_{1-10}, arilo C_{6-12}, alquilo C_{1-6} sustituido con halo hasta per-haloalquilo, arilo C_{6}-C_{12} sustituido con halo hasta per-haloarilo, cicloalquilo C_{3}-C_{12} sustituido con halo hasta per-halocicloalquilo que tiene 0-3 heteroátomos seleccionados de N, S y O, hetarilo C_{3}-C_{12} sustituido con halo hasta per-halohetarilo que tiene 1-3 heteroátomos seleccionados de O, N y S, aralquilo C_{7}-C_{24} sustituido con halo hasta per-haloaralquilo, alcarilo C_{7}-C_{24} sustituido con halo hasta per-haloalcarilo, y C(O)R_{g},R z is hydrogen, alkyl C 1-10, C 1-10 alkoxy, C 3-10 cycloalkyl having 0-3 heteroatoms, alkenyl C 2-10, C 1-10 alkenoyl, C 6-12 aryl, heteroaryl C_ {3} -C_ {12} that has 1-3 heteroatoms selected from N, S and O, alkaryl C 7-24, C 7-24 aralkyl, C 1-10 substituted alkyl, alkoxy C 1-10 substituted, aryl C 6 -C 14 substituted, cycloalkyl C_ {3} -C_ {10} substituted which has 0-3 heteroatoms selected from S, N and O, heteroaryl C_ {3-12} substituted that has 1-3 heteroatoms selected from S, N and O, alkaryl C 7-24 substituted or aralkyl C_ {7-24} substituted, and where R_ {z} is a group substituted, it is substituted with halogen until per-halo, hydroxy, alkyl C 1-10, C 3-12 cycloalkyl which has 0-3 heteroatoms selected from O, S and N, C 3-12 heteroaryl having 1-3 heteroatoms selected from N, S and O, alkoxy C 1-10, aryl C 6-12, C 1-6 alkyl substituted with halo until per-haloalkyl, aryl C 6 -C 12 substituted with halo until per-haloaryl, cycloalkyl C 3 -C 12 substituted with halo until per-halocycloalkyl having 0-3 heteroatoms selected from N, S and O, heteroaryl C 3 -C 12 substituted with halo until per-halohetaryl which has 1-3 heteroatoms selected from O, N and S, aralkyl C 7 -C 24 substituted with halo until per-haloaralkyl, alkaryl C 7 -C 24 substituted with halo until per-haloalkyl, and C (O) R g, R_{a} y R_{b} son,R_ {a} and R_ {b} are, a) independientemente hidrógeno,a) independently hydrogen, un resto basado en carbono seleccionado del grupo constituido por alquilo C_{1}-C_{10}, alcoxi C_{1}-C_{10}, cicloalquilo C_{3-10}, alquenilo C_{2-10}, alquenoílo C_{1-10}, arilo C_{6-12}, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de O, N y S, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados de N, S y O, aralquilo C_{7-24}, alcarilo C_{7-24}, alquilo C_{1-10} sustituido, alcoxi C_{1-10} sustituido, cicloalquilo C_{3-10} sustituido, que tiene 0-3 heteroátomos seleccionados de N, S y O, arilo C_{6-12} sustituido, hetarilo C_{3-12} sustituido que tiene 1-3 heteroátomos seleccionados de N, S y O, aralquilo C_{7-24} sustituido, alcarilo C_{7-24} sustituido, y donde R_{a} y R_{b} son un grupo sustituido, los mismos están sustituidos con halógeno hasta per-halo, hidroxi, alquilo C_{1-10}, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados de O, S y N, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcoxi C_{1-10}, arilo C_{6-12}, alquilo C_{1-6} sustituido con halo hasta per-haloalquilo, arilo C_{6}-C_{12} sustituido con halo hasta per-haloarilo, cicloalquilo C_{3}-C_{12} sustituido con halo que tiene 0-3 heteroátomos seleccionados de N, S y O, hasta per-halocicloalquilo, hetarilo C_{3}-C_{12} sustituido con halo hasta per-halohetarilo, aralquilo C_{7}-C_{24} sustituido con halo hasta per-haloaralquilo, alcarilo C_{7}-C_{24} sustituido con halo hasta per-haloalcarilo, y C(O)R_{g}; oa carbon based moiety selected from group consisting of C 1 -C 10 alkyl, C 1 -C 10 alkoxy, cycloalkyl C 3-10, C 2-10 alkenyl, C 1-10 alkenoyl, aryl C 6-12, C 3-12 heteroaryl which it has 1-3 heteroatoms selected from O, N and S, C 3-12 cycloalkyl having 0-3 heteroatoms selected from N, S and O, C 7-24 aralkyl, alkaryl C 7-24, C 1-10 alkyl substituted, substituted C 1-10 alkoxy, C 3-10 substituted cycloalkyl, which has 0-3 heteroatoms selected from N, S and O, aryl C 6-12 substituted, hetaryl C_ {3-12} substituted that has 1-3 heteroatoms selected from N, S and O, aralkyl C7-24 substituted, alkaryl C_ {7-24} substituted, and where R_ {a} and R_ {b} are a substituted group, they are substituted with halogen up to per-halo, hydroxy, alkyl C 1-10, C 3-12 cycloalkyl which has 0-3 heteroatoms selected from O, S and N, C 3-12 heteroaryl having 1-3 heteroatoms selected from N, S and O, alkoxy C 1-10, aryl C 6-12, C 1-6 alkyl substituted with halo until per-haloalkyl, aryl C 6 -C 12 substituted with halo until per-haloaryl, cycloalkyl C 3 -C 12 substituted with halo having 0-3 heteroatoms selected from N, S and O, up to per-halocycloalkyl, heteroaryl C 3 -C 12 substituted with halo until per-halohetaryl, aralkyl C 7 -C 24 substituted with halo until per-haloaralkyl, alkaryl C 7 -C 24 substituted with halo until per-haloalkyl, and C (O) R g; or -OSi(R_{f})_{3} donde R_{f} es hidrógeno, alquilo C_{1-10}, alcoxi C_{1-10}, cicloalquilo C_{3}-C_{10} que tiene 0-3 heteroátomos seleccionados de O, S y N, arilo C_{6-12}, hetarilo C_{3}-C_{12} que tiene 1-3 heteroátomos seleccionados de O, S y N, aralquilo C_{7-24}, alquilo C_{1-10} sustituido, alcoxi C_{1}-C_{10} sustituido, cicloalquilo C_{3}-C_{12} sustituido que tiene 0-3 heteroátomos seleccionados de O, S y N, hetarilo C_{3}-C_{12} sustituido que tiene 1-3 heteroátomos seleccionados de O, S y N, arilo C_{6-12} sustituido, y alcarilo C_{7-24} sustituido, y donde R_{f} es un grupo sustituido, el mismo está sustituido con halógeno hasta per-halo, hidroxi, alquilo C_{1-10}, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados de O, S y N, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcoxi C_{1-10}, arilo C_{6-12}, alcarilo C_{7}-C_{24}, aralquilo C_{7}-C_{24}, alquilo C_{1-6} sustituido con halo hasta per-haloalquilo, arilo C_{6}-C_{12} sustituido con halo hasta per-haloarilo, cicloalquilo C_{3}-C_{12} sustituido con halo que tiene 0-3 heteroátomos seleccionados de N, S y O, hasta per-halocicloalquilo, hetarilo C_{3}-C_{12} sustituido con halo hasta per-halohetarilo, aralquilo C_{7}-C_{24} sustituido con halo hasta per-haloaralquilo, alcarilo C_{7}-C_{24} sustituido con halo hasta per-haloalcarilo, y -C(O)R_{g}, o-OSi (R_ {f}) 3 where R_ {f} is hydrogen, C 1-10 alkyl, alkoxy C 1-10, cycloalkyl C_ {3} -C_ {10} that is 0-3 heteroatoms selected from O, S and N, aryl C_12-12, heteroaryl C_ {3} -C_ {12} that has 1-3 heteroatoms selected from O, S and N, aralkyl C 7-24, C 1-10 alkyl substituted, C 1 -C 10 alkoxy substituted, substituted C3-C12 cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C3-C12 hetaryl having 1-3 heteroatoms selected from O, S and N, aryl C 6-12 substituted, and alkaryl C_ {7-24} substituted, and where R_ {f} is a group substituted, it is substituted with halogen until per-halo, hydroxy, alkyl C 1-10, C 3-12 cycloalkyl which has 0-3 heteroatoms selected from O, S and N, C 3-12 heteroaryl having 1-3 heteroatoms selected from N, S and O, alkoxy C 1-10, aryl C 6-12, C 7 -C 24 alkaryl, aralkyl C 7 -C 24, C 1-6 alkyl halo substituted to per-haloalkyl, aryl C 6 -C 12 substituted with halo until per-haloaryl, cycloalkyl C 3 -C 12 substituted with halo having 0-3 heteroatoms selected from N, S and O, up to per-halocycloalkyl, heteroaryl C 3 -C 12 substituted with halo until per-halohetaryl, aralkyl C 7 -C 24 substituted with halo until per-haloaralkyl, alkaryl C 7 -C 24 substituted with halo until per-haloalkyl, and -C (O) R g, or b) R_{a} y R_{b} forman juntos una estructura heterocíclica de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O que tienen sustituyentes seleccionados del grupo constituido por halógeno hasta per-halo, hidroxi, alquilo C_{1-10}, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados de O, S y N, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcoxi C_{1-10}, arilo C_{6-12}, alcarilo C_{7}-C_{24}, aralquilo C_{7}-C_{24}, alquilo C_{1-6} sustituido con halo hasta per-haloalquilo, arilo C_{6}-C_{12} sustituido con halo hasta per-haloarilo, cicloalquilo C_{3}-C_{12} sustituido con halo que tiene 0-3 heteroátomos seleccionados de N, S y O, hasta per-halocicloalquilo, hetarilo C_{3}-C_{12} sustituido con halo hasta per-halohetarilo, aralquilo C_{7}-C_{24} sustituido con halo hasta per-haloaralquilo, alcarilo C_{7}-C_{24} sustituido con halo hasta per-haloalcarilo, y -C(O)R_{g}, ob) R_ {a} and R_ {b} together form a 5-7 member heterocyclic structure with 1-3 heteroatoms selected from N, S and O, or a 5-7-membered substituted heterocyclic structure with 1-3 heteroatoms selected from N, S and O that they have substituents selected from the group consisting of halogen to per-halo, hydroxy, alkyl C 1-10, C 3-12 cycloalkyl which has 0-3 heteroatoms selected from O, S and N, C 3-12 heteroaryl having 1-3 heteroatoms selected from N, S and O, alkoxy C 1-10, aryl C 6-12, C 7 -C 24 alkaryl, aralkyl C 7 -C 24, C 1-6 alkyl halo substituted to per-haloalkyl, aryl C 6 -C 12 substituted with halo until per-haloaryl, cycloalkyl C 3 -C 12 substituted with halo having 0-3 heteroatoms selected from N, S and O, up to per-halocycloalkyl, heteroaryl C 3 -C 12 substituted with halo until per-halohetaryl, aralkyl C 7 -C 24 substituted with halo until per-haloaralkyl, alkaryl C 7 -C 24 substituted with halo until per-haloalkyl, and -C (O) R g, or c) uno de R_{a} o R_{b} es -C(O)-, un grupo alquileno bivalente C_{1}-C_{5} o un grupo alquileno bivalente C_{1}-C_{5} sustituido unido al resto L para formar una estructura cíclica que tiene al menos 5 miembros,c) one of R_ {a} or R_ {b} is -C (O) -, a C 1 -C 5 bivalent alkylene group or a group C 1 -C 5 substituted bivalent alkylene attached to the remainder L to form a cyclic structure that has the minus 5 members, en donde los sustituyentes del grupo alquileno bivalente C_{1}-C_{5} sustituido se seleccionan del grupo constituido por halógeno, hidroxi, alquilo C_{1-10}, cicloalquilo C_{3-12} que tiene 0-3 heteroátomos seleccionados O, S y N, hetarilo C_{3-12} que tiene 1-3 heteroátomos seleccionados de N, S y O, alcoxi C_{1-10}, arilo C_{6-12}, alcarilo C_{7}-C_{24}, aralquilo C_{7}-C_{24}, alquilo C_{1-6} sustituido con halo hasta per-haloalquilo, arilo C_{6}-C_{12} sustituido con halo hasta per-haloarilo, cicloalquilo C_{3}-C_{12} sustituido con halo que tiene 0-3 heteroátomos seleccionados de N, S y O, hasta per-halocicloalquilo, hetarilo C_{3}-C_{12} sustituido con halo hasta per-halohetarilo, aralquilo C_{7}-C_{24} sustituido con halo hasta per-haloaralquilo, alcarilo C_{7}-C_{24} sustituido con halo hasta per-alcarilo, y -C(O)R_{g},where the alkylene group substituents C 1 -C 5 substituted bivalent are selected from the group consisting of halogen, hydroxy, alkyl C 1-10, C 3-12 cycloalkyl which has 0-3 heteroatoms selected O, S and N, C_ {3-12} heteroaryl having 1-3 heteroatoms selected from N, S and O, alkoxy C 1-10, aryl C 6-12, C 7 -C 24 alkaryl, aralkyl C 7 -C 24, C 1-6 alkyl halo substituted to per-haloalkyl, aryl C 6 -C 12 substituted with halo until per-haloaryl, cycloalkyl C 3 -C 12 substituted with halo having 0-3 heteroatoms selected from N, S and O, up to per-halocycloalkyl, heteroaryl C 3 -C 12 substituted with halo until per-halohetaryl, aralkyl C 7 -C 24 substituted with halo until per-haloaralkyl, alkaryl C 7 -C 24 substituted with halo until per-alkaryl, and -C (O) R g, donde R_{g} es alquilo C_{1-10}; -CN, -CO_{2}R_{d}, -OR_{d}, -SR_{d}, -NO_{2}, -C(O)R_{e}, -NR_{d}R_{e}, -NR_{d}C(O)OR_{e} y -NR_{d}C(O)R_{e}, y R_{d} y R_{e} se seleccionan independientemente del grupo constituido por hidrógeno, alquilo C_{1-10}, alcoxi C_{1-10}, cicloalquilo C_{3-10} que tiene 0-3 heteroátomos seleccionados de O, N y S, arilo C_{6-12}, hetarilo C_{3}-C_{12} que tiene 1-3 heteroátomos seleccionados de O, N y S y aralquilo C_{7}-C_{24}, alcarilo C_{7}-C_{24}, alquilo C_{1-10} hasta per-halosustituido, cicloalquilo C_{3}-C_{10} hasta per-halosustituido que tiene 0-3 heteroátomos seleccionados de O, N y S, arilo C_{6}-C_{14} hasta per-halosustituido, hetarilo C_{3}-C_{12} hasta per-halosustituido que tiene 1-3 heteroátomos seleccionados de O, N y S, alcarilo C_{7}-C_{24} sustituido con halo hasta per-haloalcarilo, y aralquilo C_{7}-C_{24} hasta per-halosustituido,where R g is alkyl C 1-10; -CN, -CO_ {2} R_ {d}, -OR_ {d}, -SR_ {d}, -NO_ {2}, -C (O) R_ {e}, -NR_ {d} R_ {e}, -NR_ {d} C (O) OR_ {e} and -NR_ {d} C (O) R_ {e}, and R_ {d} and R_ {e} are independently selected from the group consisting of hydrogen, C 1-10 alkyl, alkoxy C 1-10, C 3-10 cycloalkyl which has 0-3 heteroatoms selected from O, N and S, C 6-12 aryl, heteroaryl C_ {3} -C_ {12} that has 1-3 heteroatoms selected from O, N and S and aralkyl C 7 -C 24, alkaryl C 7 -C 24, alkyl C_ {1-10} until per-halosubstituted, cycloalkyl C 3 -C 10 to per-halosubstituted that is 0-3 heteroatoms selected from O, N and S, aryl C_ {6} -C_ {14} until per-halosubstituted, hetaryl C_ {3} -C_ {12} until per-halos replaced you have 1-3 heteroatoms selected from O, N and S, alkaryl C 7 -C 24 substituted with halo until per-haloalkyl, and aralkyl C_ {7} -C_ {24} until per-replaced, W se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)NR^{7}R^{7}, -C(O)-R^{7}, -NO_{2},
-OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, alquilo C_{1}-C_{10}, alcoxi C_{1}-C_{10}, alquenilo C_{2}-C_{10}, alquenoílo C_{1}-C_{10}, cicloalquilo C_{3}-C_{10} que tiene 0-3 heteroátomos seleccionados de O, S y N, arilo C_{6}-C_{14}, alcarilo C_{7}-C_{24}, aralquilo C_{7}-C_{24}, heteroarilo C_{3}-C_{12} que tiene 1-3 heteroátomos seleccionados de O, N y S, alc-heteroarilo C_{4}-C_{23} que tiene 1-3 heteroátomos seleccionados de O, N y S, alquilo C_{1}-C_{10} sustituido, alcoxi C_{1}-C_{10} sustituido, alquenilo C_{2}-C_{10} sustituido, alquenoílo C_{1}-C_{10} sustituido, cicloalquilo C_{3}-C_{10} sustituido que tiene 0-3 heteroátomos seleccionados de O, N y S, arilo C_{6}-C_{12} sustituido, hetarilo C_{3}-C_{12} sustituido que tiene 1-3 heteroátomos seleccionados de O, N y S, aralquilo C_{7}-C_{24} sustituido, alcarilo C_{7}-C_{24} sustituido, alc-heteroarilo C_{4}-C_{23} sustituido que tiene 1-3 heteroátomos seleccionados de O, N y S, y -Q-Ar;W is independently selected from the group consisting of -CN, -CO 2 R 7, -C (O) NR 7 R 7, -C (O) -R 7, -NO_ {2},
-OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C ( O) R 7, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 2 -C 10 alkenyl, C 1 -C 10 alkenyl }, C 3 -C 10 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 6 -C 14 aryl, C 7 -C 24 alkaryl, C_ aralkyl {7} -C_ {24}, C3-C12 heteroaryl having 1-3 heteroatoms selected from O, N and S, C4-C23 alc-heteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkoxy, substituted C 2 -C 10 alkenyl, C 1 alkenyl -C 10 substituted, C 3 -C 10 substituted cycloalkyl having 0-3 heteroatoms selected from O, N and S, C 6 -C 12 substituted aryl, C 3 -heteroyl - C 12 substituted having 1-3 heteroatoms selected from O, N and S, substituted C 7 -C 24 aralkyl, substituted C 7 -C 24 alkaryl, C 4 -alkyl heteroaryl -C 23 substituted which has 1-3 heteroatoms selected from O, N and S, and -Q-Ar; R^{7} se selecciona independientemente de H, alquilo C_{1}-C_{10}, alcoxi C_{1}-C_{10}, alquenilo C_{2}-C_{10}, alquenoílo C_{1}-C_{10}, cicloalquilo C_{3}-C_{10} que tiene 0-3 heteroátomos seleccionados de O, S y N, arilo C_{6}-C_{14}, heteroarilo C_{3}-C_{13} que tiene 1-3 heteroátomos seleccionados de O, N y S, alcarilo C_{7}-C_{14}, aralquilo C_{7}-C_{24}, alc-heteroarilo C_{4}-C_{23} que tiene 1-3 heteroátomos seleccionados de O, N y S, alquilo C_{1}-C_{10} hasta per-halosustituido, cicloalquilo C_{3}-C_{10} hasta per-halosustituido que tiene 0-3 heteroátomos seleccionados de O, N y S, y arilo C_{6}-C_{14} hasta per-halosustituido, hetarilo C_{3}-C_{13} hasta per-halosustituido que tiene 1-3 heteroátomos seleccionados de O, N y S, aralquilo C_{7}-C_{24} hasta per-halosustituido, alcarilo C_{7}-C_{24} hasta per-halosustituido, y alc-heteroarilo C_{4}-C_{23} hasta per-halosustituido; yR 7 is independently selected from H, C 1 -C 10 alkyl, alkoxy C 1 -C 10, alkenyl C_ {2} -C_ {10}, alkenoyl C 1 -C 10, cycloalkyl C_ {3} -C_ {10} that is 0-3 heteroatoms selected from O, S and N, aryl C 6 -C 14, heteroaryl C_ {3} -C_ {13} that has 1-3 heteroatoms selected from O, N and S, alkaryl C 7 -C 14, aralkyl C 7 -C 24, alc-heteroaryl C_ {4} -C_ {23} that has 1-3 heteroatoms selected from O, N and S, alkyl C_ {1} -C_ {{}} until per-halosubstituted, cycloalkyl C 3 -C 10 to per-halosubstituted that is 0-3 heteroatoms selected from O, N and S, and aryl C_ {6} -C_ {14} until per-halosubstituted, hetaryl C_ {3} -C_ {13} until per-halos replaced you have 1-3 heteroatoms selected from O, N and S, aralkyl C_ {7} -C_ {24} until per-halosubstituted, alkaryl C_ {7} -C_ {24} until per-replaced, and C 4 -C 23 alc-heteroaryl even per-substituted; Y cada Z se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, alquilo C_{1}-C_{10}, alcoxi C_{1}-C_{10}, alquenilo C_{2}-C_{10}, alquenoílo C_{1}-C_{10}, cicloalquilo C_{3}-C_{10} que tiene 0-3 heteroátomos seleccionados de O, N y S, arilo C_{6}-C_{14}, hetarilo C_{3}-C_{13} que tiene 1-3 heteroátomos seleccionados de O, N y S, alcarilo C_{7}-C_{24}, aralquilo C_{7}-C_{24}, alc-heteroarilo C_{4}-C_{23} que tiene 1-3 heteroátomos seleccionados de O, N y S, alquilo C_{1}-C_{10} sustituido, alcoxi C_{1}-C_{10} sustituido, alquenilo C_{2}-C_{10} sustituido, alquenoílo C_{1}-C_{10} sustituido, cicloalquilo C_{3}-C_{10} sustituido que tiene 0-3 heteroátomos seleccionados de O, N y S, arilo C_{6}-C_{12} sustituido, alcarilo C_{7}-C_{24} sustituido, aralquilo C_{7}-C_{24} sustituido y alc-heteroarilo C_{4}-C_{23} sustituido que tiene 1-3 heteroátomos seleccionados de O, N y S; en donde si Z es un grupo sustituido, los uno o más sustituyentes se seleccionan del grupo constituido por -CN, -CO_{2}R^{7}, -COR^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NO_{2}, -NR^{7}R^{7}, -NR^{7}C(O)R^{7}, y -NR^{7}C(O)OR^{7}.each Z is independently selected from group consisting of -CN, -CO 2 R 7, -C (O) R 7, -C (O) NR 7 R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, alkyl C 1 -C 10, alkoxy C 1 -C 10, alkenyl C_ {2} -C_ {10}, alkenoyl C 1 -C 10, cycloalkyl C_ {3} -C_ {10} that is 0-3 heteroatoms selected from O, N and S, aryl C 6 -C 14, heteroaryl C_ {3} -C_ {13} that has 1-3 heteroatoms selected from O, N and S, alkaryl C 7 -C 24, aralkyl C 7 -C 24, alc-heteroaryl C_ {4} -C_ {23} that has 1-3 heteroatoms selected from O, N and S, alkyl C 1 -C 10 substituted, alkoxy C 1 -C 10 substituted, alkenyl C 2 -C 10 substituted, alkenoyl C 1 -C 10 substituted, cycloalkyl C_ {3} -C_ {10} substituted which has 0-3 heteroatoms selected from O, N and S, aryl C 6 -C 12 substituted, alkaryl C 7 -C 24 substituted, aralkyl C_ {7} -C_ {24} substituted and C 4 -C 23 alc-heteroaryl substituted that has 1-3 heteroatoms selected of O, N and S; where if Z is a substituted group, the one or more Substituents are selected from the group consisting of -CN, -CO 2 R 7, -COR 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NO 2, -NR 7 R 7, -NR 7 C (O) R 7, and -NR 7 C (O) OR 7. 3. Un compuesto como se indica en la reivindicación 1, en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-,
-(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y N(R^{7})(CH_{2})_{m}-, donde m = 1-3, X^{a} es halógeno y R^{7} es como se define en la reivindicación 1.3. A compound as claimed in claim 1, wherein M is one or more bridging groups selected from the group consisting of -O-, -S-, -N (R7) -, - (CH_ {2) m -, -C (O) -, -CH (OH) -, - (CH2) m O-, - (CH2) m S -
- (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and N (R 7) (CH 2) m -, where m = 1-3, X a it is halogen and R 7 is as defined in claim 1. 4. Un compuesto de acuerdo con la reivindicación 1, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con -OH.4. A compound according to claim 1, where the cyclic structures of B and L linked directly to D are not substituted in the ortho position with -OH. 5. Un compuesto de acuerdo con la reivindicación 1, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con un resto que tenga un hidrógeno ionizable y un valor pKa de 10 o
menos.5. A compound according to claim 1, wherein the cyclic structures of B and L attached directly to D are not substituted in the ortho position with a moiety having an ionizable hydrogen and a pKa value of 10 or
less. 6. Un compuesto de acuerdo con la reivindicación 1, en donde B de la Fórmula I es un resto arilo de 6 miembros, sustituido o insustituido o un resto heteroarilo de 6 miembros, teniendo dicho resto hetarilo 1 a 4 miembros seleccionados del grupo de átomos de hetarilo constituidos por nitrógeno, oxígeno y azufre, siendo la parte restante del resto hetarilo carbono.6. A compound according to claim 1, where B of Formula I is an aryl moiety of 6 members, substituted or unsubstituted or a 6-membered heteroaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of heteroaryl atoms consisting of nitrogen, oxygen and sulfur, the remaining part of the carbon hetaryl moiety. 7. Un compuesto de la reivindicación 1, en donde B de la Fórmula I es un grupo fenilo insustituido, un grupo piridilo insustituido, un grupo pirimidinilo insustituido, un grupo fenilo sustituido con un sustituyente seleccionado del grupo constituido por halógeno y Wn en donde W y n son como se define en la reivindicación 1, un grupo pirimidinilo sustituido con un sustituyente seleccionado del grupo constituido por halógeno y Wn, en donde W y n son como se define en la reivindicación 1, o un grupo piridilo sustituido que está sustituido con un sustituyente seleccionado del grupo constituido por halógeno y Wn en donde W y n son como se define en la reivindicación 1.7. A compound of claim 1, wherein B of Formula I is an unsubstituted phenyl group, a group unsubstituted pyridyl, an unsubstituted pyrimidinyl group, a group phenyl substituted with a substituent selected from the group consisting of halogen and Wn where W and n are as defined in claim 1, a pyrimidinyl group substituted with a substituent selected from the group consisting of halogen and Wn, wherein W and n are as defined in claim 1, or a group substituted pyridyl which is substituted with a substituent selected from the group consisting of halogen and Wn where W and n are as defined in claim 1. 8. Un compuesto de la reivindicación 6 en donde B de la Fórmula I es un grupo fenilo sustituido, un grupo pirimidinilo sustituido, o grupo pirridilo que está sustituido 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por -CN, halógeno, alquilo C_{1-10}, alcoxi C_{1-10}, -OH, alquilo C_{1-10} hasta per-halosustituido, alcoxi C_{1}-C_{10} hasta per-halosustituido o fenilo sustituido con halógeno hasta per-halo.8. A compound of claim 6 wherein B of Formula I is a substituted phenyl group, a group substituted pyrimidinyl, or pyrridyl group that is substituted 1 to 3 times with one or more substituents selected from the group consisting of -CN, halogen, C 1-10 alkyl, C 1-10 alkoxy, -OH, alkyl C_ {1-10} until per-halosubstituted, alkoxy C_ {1} -C_ {{}} until per-halosubstituted or halogen substituted phenyl Until per-halo. 9. Un compuesto de la reivindicación 1, en donde L, la estructura cíclica de 6 miembros unida directamente a B, es un resto arilo sustituido o insustituido de 6 miembros o un resto hetarilo sustituido o insustituido de 6 miembros, en donde dicho resto hetarilo tiene 1-4 miembros seleccionados del grupo de heteroátomos constituidos por nitrógeno, oxígeno y azufre, siendo la parte restante de dicho resto hetarilo carbono, en donde los uno o más sustituyentes se seleccionan del grupo constituido por halógeno y Wn en donde W y n son como se define en la reivindicación 1.9. A compound of claim 1, wherein L, the 6-member cyclic structure linked directly to B, is a substituted or unsubstituted aryl moiety of 6 members or a moiety 6-member substituted or unsubstituted hetaryl, wherein said Hetaryl moiety has 1-4 members selected from group of heteroatoms consisting of nitrogen, oxygen and sulfur, the remaining part of said carbon hetaryl moiety, where the one or more substituents are selected from the group constituted by halogen and Wn where W and n are as defined in the claim 1. 10. Un compuesto de la reivindicación 8, en donde L, la estructura cíclica de 6 miembros unida directamente a D, es un grupo fenilo sustituido, fenilo insustituido, pirimidinilo sustituido, pirimidinilo insustituido, piridilo sustituido o piridilo insustituido.10. A compound of claim 8, in where L, the 6-member cyclic structure linked directly to D, is a substituted phenyl, unsubstituted phenyl, pyrimidinyl group substituted, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl. 11. Un compuesto de la reivindicación 1, en donde dicho resto cíclico sustituido L^{1} comprende un resto arilo o hetarilo de 5 ó 6 miembros, en donde dicho resto hetarilo comprende 1 a 4 miembros seleccionados del grupo de heteroátomos constituido por nitrógeno, oxígeno y azufre.11. A compound of claim 1, in wherein said substituted cyclic moiety L1 comprises a moiety 5 or 6-membered aryl or hetaryl, wherein said hetaryl moiety comprises 1 to 4 members selected from the group of heteroatoms constituted by nitrogen, oxygen and sulfur. 12. Un compuesto de la reivindicación 1, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.12. A compound of claim 1, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 13. Un compuesto de la reivindicación 3, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.13. A compound of claim 3, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 14. Un compuesto de la reivindicación 6, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.14. A compound of claim 6, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 15. Un compuesto de la reivindicación 8, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.15. A compound of claim 8, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 16. Un compuesto de la reivindicación 9, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.16. A compound of claim 9, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 17. Un compuesto de la reivindicación 10, en donde dicho resto cíclico sustituido L^{1} es fenilo, piridinilo o pirimidinilo.17. A compound of claim 10, in wherein said substituted cyclic moiety L 1 is phenyl, pyridinyl or pyrimidinyl. 18. Un compuesto de la reivindicación 14, en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, X^{a} es halógeno y R^{7} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno hasta per-halo.18. A compound of claim 14, in where M is one or more bridging groups selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, X a is halogen and R 7 is hydrogen or a carbon-based moiety of up to 24 carbon atoms, which optionally contains heteroatoms selected from N, S and O and is optionally substituted with halogen until per-halo 19. Un compuesto de la reivindicación 15, en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}, donde m = 1-3, X^{a} es halógeno y R^{7} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno hasta per-halo.19. A compound of claim 15, in where M is one or more bridging groups selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m, where m = 1-3, X a is halogen and R 7 is hydrogen or a carbon-based moiety of up to 24 carbon atoms, which contains optionally heteroatoms selected from N, S and O and is optionally substituted with halogen until per-halo 20. Un compuesto de la reivindicación 16, en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}, donde m = 1-3, X^{a} es halógeno y R^{7} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno hasta per-halo.20. A compound of claim 16, in where M is one or more bridging groups selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m, where m = 1-3, X a is halogen and R 7 is hydrogen or a carbon-based moiety of up to 24 carbon atoms, which contains optionally heteroatoms selected from N, S and O and is optionally substituted with halogen until per-halo 21. Un compuesto de la reivindicación 17, en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}, donde m = 1-3, X^{a} es halógeno y R^{7} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno hasta per-halo.21. A compound of claim 17, in where M is one or more bridging groups selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m, where m = 1-3, X a is halogen and R 7 is hydrogen or a carbon-based moiety of up to 24 carbon atoms, which contains optionally heteroatoms selected from N, S and O and is optionally substituted with halogen until per-halo 22. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.22. A compound of claim 1, in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 23. Un compuesto de la reivindicación 13 en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.23. A compound of claim 13 in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 24. Un compuesto de la reivindicación 18 en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.24. A compound of claim 18 in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 25. Un compuesto de la reivindicación 19 en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.25. A compound of claim 19 in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 26. Un compuesto de la reivindicación 20 en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.26. A compound of claim 20 in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 27. Un compuesto de la reivindicación 21 en donde L^{1} está sustituido adicionalmente 1 a 3 veces con uno o más sustituyentes seleccionados del grupo constituido por alquilo C_{1}-C_{10}, alquilo C_{1}-C_{10} sustituido hasta per-halo, -CN, -OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} sustituido hasta per-halo.27. A compound of claim 21 in where L 1 is additionally substituted 1 to 3 times with one or more substituents selected from the group consisting of alkyl C 1 -C 10, alkyl C 1 -C 10 substituted until per-halo, -CN, -OH, halogen, alkoxy C 1 -C 10 and alkoxy C 1 -C 10 substituted until per-halo 28. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido con -C(O)R_{x}.28. A compound of claim 1, in where L 1 is substituted with -C (O) R x. 29. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido con -SO_{2}R_{x}.29. A compound of claim 1, in where L1 is substituted with -SO2R_ {x}. 30. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido únicamente con -C(O)R_{x}.30. A compound of claim 1, in where L 1 is substituted only with -C (O) R_ {x}. 31. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido solamente con -SO_{2}R_{x}.31. A compound of claim 1, in where L 1 is substituted only with -SO 2 R x. 32. Un compuesto de la reivindicación 1, en donde L^{1} está sustituido con -C(O)R_{x} o -SO_{2}R_{x}, en donde R_{x} es NR_{a}R_{b}.32. A compound of claim 1, in where L 1 is substituted with -C (O) R x or -SO_ {2} R_ {x}, where R_ {x} is NR_ {a} R_ {b}. 33. Un compuesto de la reivindicación 13 en donde L^{1} está sustituido con -C(O)R_{x} o -SO_{2}R_{x}, en donde R_{x} es NR_{a}R_{b}, y R_{a} y R_{b} son33. A compound of claim 13 in where L 1 is substituted with -C (O) R x or -SO_ {2} R_ {x}, where R_ {x} is NR_ {a} R_ {b}, and R_ {a} and R_ {b} are a) independientemente hidrógeno,a) independently hydrogen, un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno, oa carbon-based moiety of up to 30 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen, or -OSi(R_{f})_{3} donde R_{f} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno; o-OSi (R_ {f}) 3 where R_ {f} is hydrogen or a carbon based moiety of up to 24 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen; or b) R_{a} y R_{b} forman juntos una estructura heterocíclica de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O sustituidos con halógeno, hidroxi o sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;
ob) R_a and Rb together form a 5-7 membered heterocyclic structure with 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic structure with 1-3 selected heteroatoms of N, S and O substituted with halogen, hydroxy or carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen;
or c) uno de R_{a} o R_{b} es -C(O)-, un grupo alquileno bivalente C_{1}-C_{5} o un grupo alquileno bivalente C_{1}-C_{5} sustituido unido al resto L para formar una estructura cíclica que tiene al menos 5 miembros, en donde los sustituyentes del grupo alquileno bivalente C_{1}-C_{5} sustituido se seleccionan del grupo constituido por halógeno, hidroxi, y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados a partir de N, S y O y están sustituidos opcionalmente con halógeno.c) one of R_ {a} or R_ {b} is -C (O) -, a C 1 -C 5 bivalent alkylene group or a group C 1 -C 5 substituted bivalent alkylene attached to the remainder L to form a cyclic structure that has the minus 5 members, where the alkylene group substituents C 1 -C 5 substituted bivalent are selected from the group consisting of halogen, hydroxy, and substituents carbon based up to 24 carbon atoms, containing optionally heteroatoms selected from N, S and O and are optionally substituted with halogen. 34. Un compuesto de la reivindicación 18 en donde L^{1} está sustituido con -C(O)R_{x} o -SO_{2}R_{x}, en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.34. A compound of claim 18 in where L 1 is substituted with -C (O) R x or -SO_ {2} R_ {x}, where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R b are independently hydrogen or a residue based on carbon of up to 30 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, hydroxy and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen. 35. Un compuesto de la reivindicación 19 en donde L^{1} está sustituido con -C(O)R_{x}, en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.35. A compound of claim 19 in where L 1 is substituted with -C (O) R x, in where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R_ {b} are independently hydrogen or a carbon based moiety of up to 30 carbon atoms that optionally contain heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon based substituents up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen 36. Un compuesto de la reivindicación 20, en donde L^{1} está sustituido con -C(O)R_{x} o -SO_{2}R_{x}, en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basado en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.36. A compound of claim 20, in where L 1 is substituted with -C (O) R x or -SO_ {2} R_ {x}, where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R b are independently hydrogen or a residue based on carbon of up to 30 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, hydroxy and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen. 37. Un compuesto de la reivindicación 21 en donde L^{1} está sustituido con -C(O)R_{x} o -SO_{2}R_{x}, en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y heteroátomos basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.37. A compound of claim 21 in where L 1 is substituted with -C (O) R x or -SO_ {2} R_ {x}, where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R b are independently hydrogen or a residue based on carbon of up to 30 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, hydroxy and heteroatoms based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen. 38. Un compuesto de la Fórmula I:38. A compound of Formula I: (I)A - D - B(I) A - D - B o una sal farmacéuticamente aceptable del mismo, en dondeor a pharmaceutically salt acceptable of it, in where D es -NH-C(O)-NH-,D is -NH-C (O) -NH-, A es un resto sustituido de hasta 40 átomos de carbono de la fórmula: -L-(M-L^{1})_{q}, donde L es un resto arilo de seis miembros o un resto hetarilo de 6 miembros unido directamente a D, L^{1} comprende un resto cíclico sustituido que tiene al menos 5 miembros, M es un grupo formador de puentes que tiene al menos un átomo, q es un número entero de 1-3; y cada estructura cíclica de L y L^{1} contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre, yA is a substituted residue of up to 40 atoms of carbon of the formula: -L- (M-L 1) q, where L is an aryl residue of six members or a hetaryl residue of 6 members directly attached to D, L1 comprises a cyclic moiety substituted that has at least 5 members, M is a forming group of bridges that has at least one atom, which is an integer of 1-3; and each cyclic structure of L and L1 Contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and B es un resto arilo o heteroarilo sustituido o insustituido, hasta tricíclico, que tiene hasta 30 átomos de carbono con al menos una estructura cíclica de 6 miembros unida directamente a D que contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre,B is a substituted aryl or heteroaryl moiety or unsubstituted, even tricyclic, which has up to 30 atoms of carbon with at least one 6-member cyclic structure attached directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, en donde L^{1} está sustituido con al menos un sustituyente seleccionado del grupo constituido por -SO_{2}R_{x}, -C(O)R_{x} y -C(NR_{y})R_{z},wherein L 1 is substituted with at least one substituent selected from the group consisting of -SO_ {2} R_ {x}, -C (O) R_ {x} y -C (NR_ {y}) R_ {z}, R_{y} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hasta per-halo,R y is hydrogen or a residue based on carbon of up to 24 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, up to per-halo, R_{z} es hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;R_Z is hydrogen or a residue based on carbon of up to 30 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, hydroxy and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen; R_{x} es R_{z} o NR_{a}R_{b} donde R_{a} y R_{b} sonR_ {x} is R_ {z} or NR_ {a} R_ {b} where R_ {a} and R_ {b} are a) independientemente hidrógeno,a) independently hydrogen, un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno, oa carbon-based moiety of up to 30 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen, or -OSi(R_{f})_{3} donde R_{f} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno; o-OSi (R_ {f}) 3 where R_ {f} is hydrogen or a carbon based moiety of up to 24 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen; or b) R_{a} y R_{b} forman juntos una estructura heterocíclica de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O sustituidos con halógeno, hidroxi o sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;
ob) R_a and Rb together form a 5-7 membered heterocyclic structure with 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic structure with 1-3 selected heteroatoms of N, S and O substituted with halogen, hydroxy or carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen;
or c) uno de R_{a} o R_{b} es -C(O)-, un grupo alquileno bivalente C_{1}-C_{5} o un grupo alquileno bivalente C_{1}-C_{5} sustituido unido al resto L para formar una estructura cíclica que tiene al menos 5 miembros, en donde los sustituyentes del grupo alquileno bivalente C_{1}-C_{5} sustituido se seleccionan del grupo constituido por halógeno, hidroxi, y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;c) one of R_ {a} or R_ {b} is -C (O) -, a C 1 -C 5 bivalent alkylene group or a group C 1 -C 5 substituted bivalent alkylene attached to the remainder L to form a cyclic structure that has the minus 5 members, where the alkylene group substituents C 1 -C 5 substituted bivalent are selected from the group consisting of halogen, hydroxy, and substituents based in carbon of up to 24 carbon atoms, which contain optionally heteroatoms selected from N, S and O and are optionally substituted with halogen; donde B está sustituido, L está sustituido o L^{1} está sustituido adicionalmente, los sustituyentes se seleccionan del grupo constituido por halógeno hasta per-halo, y Wn, donde n es 0-3;where B is substituted, L is substituted or L1 is further substituted, the substituents are select from the group consisting of halogen up to per-halo, and Wn, where n is 0-3; en donde cada W se selecciona independientemente del grupo constituido por -CN, -CO_{2}R_{7}, -C(O)NR^{7}R^{7}, -C(O)-R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, -Q-Ar, y restos basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, NO_{2}, -NR^{7}C(O)R^{7}, -NR^{7}C(O)OR^{7} y halógeno hasta per-halo; seleccionándose cada R^{7} independientemente de H o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno,where each W is independently selected of the group consisting of -CN, -CO 2 R 7, -C (O) NR 7 R 7, -C (O) -R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, -Q-Ar, and residues carbon based up to 24 carbon atoms, containing optionally heteroatoms selected from N, S and O and are optionally substituted with one or more selected substituents regardless of the group consisting of -CN, -CO2R7, -C (O) R 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NR 7 R 7, NO 2, -NR 7 C (O) R 7, -NR 7 C (O) OR 7 and halogen up to per-halo; selecting every R 7 regardless of H or a carbon-based moiety of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and is optionally substituted with halogen, en donde Q es -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, y X^{a} es halógeno;where Q is -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, and X a is halogen; Ar es una estructura aromática de 5 ó 6 miembros que contiene 0-2 miembros seleccionados del grupo constituido por nitrógeno, oxígeno y azufre, que está sustituida opcionalmente con halógeno, hasta per-halo, y sustituida opcionalmente con Z_{n1}, en donde n1 es 0 a 3 y cada Z se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, y un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con uno o más sustituyentes que se seleccionan del grupo constituido por -CN, -CO_{2}R^{7}, -COR^{7},
-C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NO_{2}, -NR^{7}R^{7}, -NR^{7}C(O)R^{7}, y -NR^{7}C(O)OR^{7}, siendo R^{7} como se ha definido arriba;
yAr is a 5 or 6 member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted with halogen, to per-halo, and optionally substituted with Z_1, where n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO2R7, -C (O) R7, -C (O) NR7 R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR ^ {7}, -NR 7 C (O) R 7, and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and is optionally substituted with one or more substituents that are selected from the group consisting of -CN, -CO 2 R 7, -COR 7,
-C (O) NR 7 R 7, -OR 7, -SR 7, -NO 2, -NR 7 R 7, -NR 7 C (O) R 7, and -NR 7 C (O) OR 7, where R 7 is as defined above;
Y en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, y X^{a} es halógeno.where M is one or more groups forming bridges selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, and X a is halogen. 39. Un compuesto de la Fórmula I:39. A compound of Formula I: (I)A - D - B(I) A - D - B o una sal farmacéuticamente aceptablemente del mismo, en dondeor a pharmaceutically salt acceptably of it, in where D es -NH-C(O)-NH-,D is -NH-C (O) -NH-, A es un resto sustituido de hasta 40 átomos de carbono de la fórmula: -L-(M-L^{1})_{q}, donde L es un resto fenilo o peritoneal insustituido o sustituido unido directamente a D, L^{1} comprende un resto fenilo, peritoneal o pirimidinilo sustituido, M es un grupo formador de puentes que tiene al menos un átomo, q es un número entero de 1 a 3; yA is a substituted residue of up to 40 atoms of carbon of the formula: -L- (M-L 1) q, where L is an unsubstituted or substituted phenyl or peritoneal moiety directly linked to D, L1 comprises a phenyl moiety, peritoneal or substituted pyrimidinyl, M is a forming group of bridges that have at least one atom, q is an integer from 1 to 3; Y B es un resto fenilo o piridina sustituido o insustituido unido directamente a D,B is a substituted phenyl or pyridine moiety or unsubstituted directly linked to D, en donde L^{1} está sustituido con al menos un sustituyente seleccionado del grupo constituido por -SO_{2}R_{x}, -C(O)R_{x} y -C(NR_{y})R_{z},wherein L 1 is substituted with at least one substituent selected from the group consisting of -SO_ {2} R_ {x}, -C (O) R_ {x} y -C (NR_ {y}) R_ {z}, R_{y} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hasta per-halo, y;R y is hydrogen or a residue based on carbon of up to 24 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, up to per-halo, and; R_{z} es hidrógeno o un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;R_Z is hydrogen or a residue based on carbon of up to 30 carbon atoms that optionally contains heteroatoms selected from N, S and O and is substituted optionally with halogen, hydroxy and substituents based on carbon of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen; R_{x} es R_{z} o NR_{a}R_{b}, donde R_{a} y R_{b} sonR_ {x} is R_ {z} or NR_ {a} R_ {b}, where R_ {a} and R_ {b} are a) independientemente hidrógeno,a) independently hydrogen, un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno, oa carbon-based moiety of up to 30 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen, or -OSi(R_{f})_{3}, donde R_{f} es hidrógeno o un resto basado en carbono de hasta 24 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno; o-OSi (R_ {f}) 3, where R_ {f} is hydrogen or a carbon based moiety of up to 24 atoms of carbon optionally containing heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen; or b) R_{a} y R_{b} forman juntos una estructura heterocíclica de 5-7 miembros de 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros con 1-3 heteroátomos seleccionados de N, S y O sustituidos con halógeno, hidroxi o sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno; ob) R_ {a} and R_ {b} together form a 5-7 heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a 5-7-membered substituted heterocyclic structure with 1-3 heteroatoms selected from N, S and O halogen substituted, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are substituted optionally with halogen; or c) uno de R_{a} o R_{b} es -C(O)-, un grupo alquileno C_{1}-C_{5} bivalente o un grupo alquileno C_{1}-C_{5} bivalente sustituido unido al resto L para formar una estructura cíclica que tiene al menos 5 miembros, en donde los sustituyentes del grupo alquileno C_{1}-C_{5} bivalente sustituido se seleccionan del grupo constituido por halógeno, hidroxi, y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno;c) one of R_ {a} or R_ {b} is -C (O) -, a C 1 -C 5 alkylene group bivalent or a group C 1 -C 5 alkylene substituted bivalent attached to the remainder L to form a cyclic structure that has the minus 5 members, where the alkylene group substituents C 1 -C 5 substituted bivalent are selected from the group consisting of halogen, hydroxy, and substituents carbon based up to 24 carbon atoms, containing optionally heteroatoms selected from N, S and O and are optionally substituted with halogen; donde B está sustituido, L está sustituido o L^{1} está sustituido adicionalmente, los sustituyentes se seleccionan del grupo constituido por halógeno, hasta per-halo y Wn, donde n es 0-3;where B is substituted, L is substituted or L1 is further substituted, the substituents are select from the group consisting of halogen, up to per-halo and Wn, where n is 0-3; en donde cada W se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)NR^{7}R^{7}, -C(O)-R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, -Q-Ar, y restos basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NO_{2}, -NR^{7}C(O)R^{7}, -NR^{7}C(O)OR^{7} y halógeno hasta per-halo; seleccionándose cada R^{7} independientemente de H o un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno,where each W is independently selected from the group consisting of -CN, -CO 2 R 7, -C (O) NR 7 R 7, -C (O) -R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, -Q-Ar, and residues carbon based up to 24 carbon atoms, containing optionally heteroatoms selected from N, S and O and are optionally substituted with one or more selected substituents regardless of the group consisting of -CN, -CO2R7, -C (O) R 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NR 7 R 7, -NO 2, -NR 7 C (O) R 7, -NR 7 C (O) OR 7 and halogen up to per-halo; selecting every R 7 regardless of H or a carbon-based moiety of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and is optionally substituted with halogen, en donde Q es -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, y X^{a} es halógeno;where Q is -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, and X a is halogen; Ar es una estructura aromática de 5 ó 6 miembros que contiene 0-2 miembros seleccionados del grupo constituido por nitrógeno, oxígeno y azufre, que está sustituida opcionalmente con halógeno, hasta per-halo, y sustituida opcionalmente con Z_{n1} en donde n1 es 0 a 3 y cada Z se selecciona independientemente del grupo constituido por -CN, -CO_{2}R^{7}, -C(O)R^{7}, -C(O)NR^{7}R^{7}, -NO_{2}, -OR^{7}, -SR^{7}, -NR^{7}R^{7}, -NR^{7}C(O)OR^{7}, -NR^{7}C(O)R^{7}, y un resto basado en carbono de hasta 24 átomos de carbono, que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con uno o más sustituyentes seleccionados del grupo constituido por -CN, -CO_{2}R^{7}, -COR^{7}, -C(O)NR^{7}R^{7}, -OR^{7}, -SR^{7}, -NO_{2}, -NR^{7}R^{7}, -NR^{7}C(O)R^{7}, y -NR^{7}C(O)OR^{7}; yAr is an aromatic structure of 5 or 6 members containing 0-2 selected group members consisting of nitrogen, oxygen and sulfur, which is substituted optionally with halogen, up to per-halo, and optionally substituted with Z_ {n1} where n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO 2 R 7, -C (O) R 7, -C (O) NR 7 R 7, -NO 2, -OR 7, -SR 7, -NR 7 R 7, -NR 7 C (O) OR 7, -NR 7 C (O) R 7, and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and is optionally substituted with one or more substituents selected from the group consisting of -CN, -CO 2 R 7, -COR 7, -C (O) NR 7 R 7, -OR 7, -SR 7, -NO 2, -NR 7 R 7, -NR 7 C (O) R 7, and -NR 7 C (O) OR 7; Y en donde M es uno o más grupos formadores de puentes seleccionados del grupo constituido por -O-, -S-, -N(R^{7})-, -(CH_{2})_{m}-, -C(O)-, -CH(OH)-, -(CH_{2})_{m}O-, -(CH_{2})_{m}S-, -(CH_{2})_{m}N(R^{7})-, -O(CH_{2})_{m}- CHX^{a}-, -CX^{a}_{2}-, -S-(CH_{2})_{m}- y -N(R^{7})(CH_{2})_{m}-, donde m = 1-3, y X^{a} es halógeno.where M is one or more groups forming bridges selected from the group consisting of -O-, -S-, -N (R 7) -, - (CH 2) m -, -C (O) -, -CH (OH) -, - (CH 2) m O-, - (CH 2) m S-, - (CH 2) m N (R 7) -, -O (CH 2) m - CHX a -, -CX a 2 -, -S- (CH 2) m - and -N (R 7) (CH 2) m -, where m = 1-3, and X a is halogen. 40. Un compuesto de acuerdo con la reivindicación 38, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con -OH.40. A compound according to the claim 38, wherein the cyclic structures of B and L attached directly to D are not substituted in the ortho position with -OH. 41. Un compuesto de acuerdo con la reivindicación 38, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con un resto que tenga un hidrógeno ionizable y un valor pKa de 10 o menos.41. A compound according to the claim 38, wherein the cyclic structures of B and L attached directly to D are not substituted in the ortho position with a remainder that has an ionizable hydrogen and a pKa value of 10 or less. 42. Un compuesto de acuerdo con la reivindicación 39, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con -OH.42. A compound according to the claim 39, wherein the cyclic structures of B and L attached directly to D are not substituted in the ortho position with -OH. 43. Un compuesto de acuerdo con la reivindicación 39, en donde las estructuras cíclicas de B y L unidas directamente a D no están sustituidas en la posición orto con un resto que tenga un hidrógeno ionizable y un valor pKa de 10 o menos.43. A compound according to the claim 39, wherein the cyclic structures of B and L attached directly to D are not substituted in the ortho position with a remainder that has an ionizable hydrogen and a pKa value of 10 or less. 44. Un compuesto de acuerdo con la reivindicación 38, en donde los sustituyentes para B y L y sustituyentes adicionales para L^{1} se seleccionan del grupo constituido por alquilo C_{1}-C_{10} hasta alquilo C_{1}-C_{10} per-halosustituido, CN, OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} hasta per-halosustituido.44. A compound according to the claim 38, wherein the substituents for B and L and Additional substituents for L1 are selected from the group consisting of C 1 -C 10 alkyl up to C 1 -C 10 alkyl per-halosubstituted, CN, OH, halogen, alkoxy C 1 -C 10 and alkoxy C_ {1} -C_ {{}} until per-replaced. 45. Un compuesto de acuerdo con la reivindicación 39, en donde los sustituyentes para B y L y sustituyentes adicionales para L^{1} se seleccionan del grupo constituido por alquilo C_{1}-C_{10} hasta alquilo C_{1}-C_{10} per-halosustituido, CN, OH, halógeno, alcoxi C_{1}-C_{10} y alcoxi C_{1}-C_{10} hasta per-halosustituido.45. A compound according to the claim 39, wherein the substituents for B and L and Additional substituents for L1 are selected from the group consisting of C 1 -C 10 alkyl up to C 1 -C 10 alkyl per-halosubstituted, CN, OH, halogen, alkoxy C 1 -C 10 and alkoxy C_ {1} -C_ {{}} until per-replaced. 46. Un compuesto de la reivindicación 38, en donde L^{1} está sustituido con C(O)R_{x} o SO_{2}R_{x}.46. A compound of claim 38, in where L 1 is substituted with C (O) R x or SO_ {2} R_ {x}. 47. Un compuesto de la reivindicación 39, en donde L^{1} está sustituido con C(O)R_{x} o SO_{2}R_{x}.47. A compound of claim 39, in where L 1 is substituted with C (O) R x or SO_ {2} R_ {x}. 48. Un compuesto de la reivindicación 46 en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno y un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.48. A compound of claim 46 in where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R_ {b} are independently hydrogen and a carbon-based moiety of up to 30 carbon atoms that optionally contain heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon based substituents up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen 49. Un compuesto de la reivindicación 47, en donde R_{x} es NR_{a}R_{b} y R_{a} y R_{b} son independientemente hidrógeno y un resto basado en carbono de hasta 30 átomos de carbono que contiene opcionalmente heteroátomos seleccionados de N, S y O y está sustituido opcionalmente con halógeno, hidroxi y sustituyentes basados en carbono de hasta 24 átomos de carbono, que contienen opcionalmente heteroátomos seleccionados de N, S y O y están sustituidos opcionalmente con halógeno.49. A compound of claim 47, in where R_ {x} is NR_ {a} R_ {b} and R_ {a} and R_ {b} are independently hydrogen and a carbon-based moiety of up to 30 carbon atoms that optionally contain heteroatoms selected from N, S and O and is optionally substituted with halogen, hydroxy and carbon based substituents up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted with halogen 50. Un compuesto de la reivindicación 1 que es una sal farmacéuticamente aceptable de un compuesto de la Fórmula I seleccionado del grupo constituido por50. A compound of claim 1 which is a pharmaceutically acceptable salt of a compound of Formula I selected from the group consisting of a) sales básicas de ácidos orgánicos y ácidos inorgánicos seleccionados del grupo constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido metanosulfónico, ácido trifluorosulfónico, ácido bencenosulfónico, ácido p-tolueno-sulfónico (sal tosilato), ácido 1-naftaleno-sulfónico, ácido 2-naftaleno-sulfónico, ácido acético, ácido trifluoroacético, ácido málico, ácido tartárico, ácido cítrico, ácido láctico, ácido oxálico, ácido succínico, ácido fumárico, ácido maleico, ácido benzoico, ácido salicílico, ácido fenilacético, y ácido mandélico;
ya) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1- acid naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
Y b) sales ácidas de bases orgánicas e inorgánicas que contienen cationes seleccionados del grupo constituido por cationes alcalinos, cationes alcalinotérreos, el catión amonio, cationes amonio con sustituyentes alifáticos y cationes amonio con sustituyentes aromáticos.b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkali cations, alkaline earth cations, the ammonium cation, ammonium cations with aliphatic substituents and ammonium cations with aromatic substituents 51. Un compuesto de la reivindicación 2, que es una sal farmacéuticamente aceptable de un compuesto de la Fórmula I seleccionado del grupo constituido por51. A compound of claim 2, which is a pharmaceutically acceptable salt of a compound of Formula I selected from the group consisting of a) sales básicas de ácidos orgánicos y ácidos inorgánicos seleccionados del grupo constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido metanosulfónico, ácido trifluorosulfónico, ácido bencenosulfónico, ácido p-tolueno-sulfónico (sal tosilato), ácido 1-naftaleno-sulfónico, ácido 2-naftaleno-sulfónico, ácido acético, ácido trifluoroacético, ácido málico, ácido tartárico, ácido cítrico, ácido láctico, ácido oxálico, ácido succínico, ácido fumárico, ácido maleico, ácido benzoico, ácido salicílico, ácido fenilacético, y ácido mandélico; ya) basic salts of organic acids and acids inorganic selected from the group consisting of acid hydrochloric, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, acid benzenesulfonic acid p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, acid 2-naphthalene sulfonic acid acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, acid fumaric, maleic acid, benzoic acid, salicylic acid, acid phenylacetic, and mandelic acid; Y b) sales ácidas de bases orgánicas e inorgánicas que contienen cationes seleccionados del grupo constituido por cationes alcalinos, cationes alcalinotérreos, el catión amonio, cationes amonio con sustituyentes alifáticos y cationes amonio con sustituyentes aromáticos.b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkali cations, alkaline earth cations, the ammonium cation, ammonium cations with aliphatic substituents and ammonium cations with aromatic substituents 52. Un compuesto de la reivindicación 33 que es una sal farmacéuticamente aceptable de un compuesto de la Fórmula I seleccionado del grupo constituido por52. A compound of claim 33 which is a pharmaceutically acceptable salt of a compound of Formula I selected from the group consisting of a) sales básicas de ácidos orgánicos y ácidos inorgánicos seleccionados del grupo constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido metanosulfónico, ácido trifluorosulfónico, ácido bencenosulfónico, ácido p-tolueno-sulfónico (sal tosilato), ácido 1-naftaleno-sulfónico, ácido 2-naftaleno-sulfónico, ácido acético, ácido trifluoroacético, ácido málico, ácido tartárico, ácido cítrico, ácido láctico, ácido oxálico, ácido succínico, ácido fumárico, ácido maleico, ácido benzoico, ácido salicílico, ácido fenilacético, y ácido mandélico; ya) basic salts of organic acids and acids inorganic selected from the group consisting of acid hydrochloric, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, acid benzenesulfonic acid p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, acid 2-naphthalene sulfonic acid acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, acid fumaric, maleic acid, benzoic acid, salicylic acid, acid phenylacetic, and mandelic acid; Y b) sales ácidas de bases orgánicas e inorgánicas que contienen cationes seleccionados del grupo constituido por cationes alcalinos, cationes alcalinotérreos, el catión amonio, cationes amonio con sustituyentes alifáticos y cationes amonio con sustituyentes aromáticos.b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkali cations, alkaline earth cations, the ammonium cation, ammonium cations with aliphatic substituents and ammonium cations with aromatic substituents 53. Un compuesto de la reivindicación 38, que es una sal farmacéuticamente aceptable de un compuesto de la Fórmula I seleccionado del grupo constituido por:53. A compound of claim 38, which is a pharmaceutically acceptable salt of a compound of Formula I selected from the group consisting of: a) sales básicas de ácidos orgánicos y ácidos inorgánicos seleccionados del grupo constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido metanosulfónico, ácido trifluorosulfónico, ácido bencenosulfónico, ácido p-tolueno-sulfónico (sal tosilato), ácido 1-naftaleno-sulfónico, ácido 2-naftaleno-sulfónico, ácido acético, ácido trifluoroacético, ácido málico, ácido tartárico, ácido cítrico, ácido láctico, ácido oxálico, ácido succínico, ácido fumárico, ácido maleico, ácido benzoico, ácido salicílico, ácido fenilacético, y ácido mandélico; ya) basic salts of organic acids and acids inorganic selected from the group consisting of acid hydrochloric, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, acid benzenesulfonic acid p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, acid 2-naphthalene sulfonic acid acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, acid fumaric, maleic acid, benzoic acid, salicylic acid, acid phenylacetic, and mandelic acid; Y b) sales ácidas de bases orgánicas e inorgánicas que contienen cationes seleccionados del grupo constituido por cationes alcalinos, cationes alcalinotérreos, el catión amonio, cationes amonio con sustituyentes alifáticos y cationes amonio con sustituyentes aromáticos.b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkali cations, alkaline earth cations, the ammonium cation, ammonium cations with aliphatic substituents and ammonium cations with aromatic substituents 54. Un compuesto de la reivindicación 39 que es una sal farmacéuticamente aceptable de un compuesto de la Fórmula I seleccionada del grupo constituido por54. A compound of claim 39 which is a pharmaceutically acceptable salt of a compound of Formula I selected from the group consisting of a) sales básicas de ácidos orgánicos y ácidos inorgánicos seleccionados del grupo constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido metanosulfónico, ácido trifluorosulfónico, ácido bencenosulfónico, ácido p-tolueno-sulfónico (sal tosilato), ácido 1-naftaleno-sulfónico, ácido 2-naftaleno-sulfónico, ácido acético, ácido trifluoroacético, ácido málico, ácido tartárico, ácido cítrico, ácido láctico, ácido oxálico, ácido succínico, ácido fumárico, ácido maleico, ácido benzoico, ácido salicílico, ácido fenilacético, y ácido mandélico; ya) basic salts of organic acids and acids inorganic selected from the group consisting of acid hydrochloric, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, acid benzenesulfonic acid p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, acid 2-naphthalene sulfonic acid acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, acid fumaric, maleic acid, benzoic acid, salicylic acid, acid phenylacetic, and mandelic acid; Y b) sales ácidas de bases orgánicas e inorgánicas que contienen cationes seleccionados del grupo constituido por cationes alcalinos, cationes alcalinotérreos, el catión amonio, cationes amonio con sustituyentes alifáticos y cationes amonio con sustituyentes aromáticos.b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkali cations, alkaline earth cations, the ammonium cation, ammonium cations with aliphatic substituents and ammonium cations with aromatic substituents 55. Una composición farmacéutica que comprende un compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable de un compuesto de la Fórmula I, y un vehículo fisiológicamente aceptable.55. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically salt acceptable of a compound of Formula I, and a vehicle Physiologically acceptable. 56. Una composición farmacéutica que comprende un compuesto de la reivindicación 2 consistente con la Fórmula I o una sal farmacéuticamente aceptable del mismo, y un vehículo fisiológicamente aceptable.56. A pharmaceutical composition comprising a compound of claim 2 consistent with Formula I or a pharmaceutically acceptable salt thereof, and a vehicle Physiologically acceptable. 57. Una composición farmacéutica que comprende un compuesto de la reivindicación 33 consistente con la Fórmula I o una sal farmacéuticamente aceptable de la misma, y un vehículo fisiológicamente aceptable.57. A pharmaceutical composition comprising a compound of claim 33 consistent with Formula I or a pharmaceutically acceptable salt thereof, and a vehicle Physiologically acceptable. 58. Una composición farmacéutica que comprende un compuesto de la reivindicación 38 consistente con la Fórmula I o una sal farmacéuticamente aceptable de la misma, y un vehículo fisiológicamente aceptable.58. A pharmaceutical composition comprising a compound of claim 38 consistent with Formula I or a pharmaceutically acceptable salt thereof, and a vehicle Physiologically acceptable. 59. Una composición farmacéutica que comprende un compuesto de la reivindicación 39 consistente con la Fórmula I o una sal farmacéuticamente aceptable de la misma, y un vehículo fisiológicamente aceptable.59. A pharmaceutical composition comprising a compound of claim 39 consistent with Formula I or a pharmaceutically acceptable salt thereof, and a vehicle Physiologically acceptable. 60. Un compuesto seleccionado del grupo constituido por60. A compound selected from the group Constituted by 3-terc-butil-fenil-ureas de la Tabla 1 anterior;3-tert-butyl-phenyl-ureas from Table 1 above; 5-terc-butil-2-metoxifenil-ureas de la Tabla 2 anterior;5-tert-butyl-2-methoxyphenyl ureas from Table 2 above; 5-(trifluorometil)-2-fenil-ureas de la Tabla 3 anterior;5- (trifluoromethyl) -2-phenyl ureas from Table 3 above; 3-(trifluorometil)-4-clorofenil-ureas de la Tabla 4 anterior;3- (trifluoromethyl) -4-chlorophenyl ureas from Table 4 above; 3-(trifluorometil)-4-bromofenil-ureas de la tabla 5 anterior;3- (trifluoromethyl) -4-bromophenyl ureas from table 5 above; 5-(trifluorometil)-4-cloro-2-metoxifenil-ureas de la Tabla 6 anterior; y5- (trifluoromethyl) -4-chloro-2-methoxyphenyl ureas from Table 6 above; Y ureas 101-103 de la Tabla 7 anterior.ureas 101-103 of Table 7 previous. 61. Un compuesto seleccionado del grupo constituido por61. A compound selected from the group Constituted by las 3-terc-butil-fenil-ureas:the 3-tert-butyl-phenyl-ureas: N-(3-terc-butilfenil)-N'-(4-(3-(N-metilcarbamoil)fenoxi)-fenil-urea y N - (3- tert -butylphenyl) - N ' - (4- (3- ( N- methylcarbamoyl) phenoxy) -phenyl-urea and N-(3-terc-butilfenil)-N'-(4-(4-acetilfenoxi)fenil-urea; N - (3- tert -butylphenyl) - N ' - (4- (4-acetylphenoxy) phenyl urea; las 5-terc-butil-2-metoxifenil-ureas:5- tert -butyl-2-methoxyphenyl ureas: N-(5-terc-butil-2-metoxifenil)-N'-(4-(1,3-dioxoisoindol-in-5-iloxi)fenil)-urea, N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (1,3-dioxoisoindole-in-5-yloxy) phenyl) -urea, N-(5-terc-butil-2-metoxifenil)-N'-(4-(1-oxoisoindolin-5-iloxi)fenil)-urea, N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (1-oxoisoindolin-5-yloxy) phenyl) -urea, N-(5-terc-butil-2-metoxifenil)-N'-(4-(4-metoxi-3-(N-metilcarbamoil)fenoxi)fenil)-urea y N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (4-methoxy-3- ( N- methylcarbamoyl) phenoxy) phenyl) -urea and N-(5-terc-butil-2-metoxifenil)-N'-(4-(3-(N-metilcarbamoil)fenoxi)fenil)-urea; N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (3- ( N- methylcarbamoyl) phenoxy) phenyl) -urea; las 2-metoxi-5-trifluorometil)fenil-ureas:the 2-methoxy-5-trifluoromethyl) phenyl ureas: N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-(2-carbamoil-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3- (2-carbamoyl-4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-carbamoil-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2-carbamoyl-4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiltio)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridylthio) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea; N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea; las 4-cloro-3-(trifluorometil)fenil-ureas:the 4-Chloro-3- (trifluoromethyl) phenyl ureas: N-(4-cloro-3-(trifluorometil)fenil)-N'-(3-(2-carbamoil-4-piridiloxi)fenil)urea, N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N-(4-cloro-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-cloro-3-(trifluorometil)fenil)-N'-(4-(2-carbamoil-4-piridiloxi)fenil)-urea y N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) -urea and N-(4-cloro-3-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea; N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea; las 4-bromo-3-(trifluorometil)fenil-ureas:the 4-Bromo-3- (trifluoromethyl) phenyl ureas: N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiltio)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridylthio) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (4-bromo-3- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea; y N - (4-bromo-3- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea; Y las 2-metoxi-4-cloro-5-(trifluorometil)fenil-ureas:the 2-methoxy-4-chloro-5- (trifluoromethyl) phenyl ureas: N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)-fenil-urea, N - (2-Methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) -phenyl-urea, N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea. N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea. 62. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto de la Fórmula I de la reivindicación 1.62. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound of Formula I of the claim 1. 63. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto de la Fórmula I de la reivindicación 33.63. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound of Formula I of the claim 33. 64. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto de la Fórmula I de la reivindicación 38.64. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound of Formula I of the claim 38. 65. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto de la Fórmula I de la reivindicación 39.65. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound of Formula I of the claim 39. 66. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto seleccionado del grupo constituido por66. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound selected from the group Constituted by 3-terc-butil-fenil-ureas de la Tabla 1 anterior;3-tert-butyl-phenyl-ureas from Table 1 above; 5-terc-butil-2-metoxifenil-ureas de la Tabla 2 anterior;5-tert-butyl-2-methoxyphenyl ureas from Table 2 above; 5-(trifluorometil)-2-fenil-ureas de la Tabla 3 anterior;5- (trifluoromethyl) -2-phenyl ureas from Table 3 above; 3-(trifluorometil)-4-clorofenil-ureas de la Tabla 4 anterior;3- (trifluoromethyl) -4-chlorophenyl ureas from Table 4 above; 3-(trifluorometil)-4-bromofenil-ureas de la Tabla 5 anterior;3- (trifluoromethyl) -4-bromophenyl ureas from Table 5 above; 5-(trifluorometil)-4-cloro-2-metoxifenil-ureas de la Tabla 6 anterior; y5- (trifluoromethyl) -4-chloro-2-methoxyphenyl ureas from Table 6 above; Y ureas 101-103 de la Tabla 7 anterior.ureas 101-103 of Table 7 previous. 
         \newpage\ newpage
67. Un método para el tratamiento del crecimiento de una célula cancerosa mediado por la quinasa raf, que comprende administrar un compuesto seleccionado del grupo constituido por67. A method for the treatment of growth of a cancer cell mediated by raf kinase, which comprises administering a compound selected from the group Constituted by las 3-terc-butil-fenil-ureas:the 3-tert-butyl-phenyl-ureas: N-(3-terc-butilfenil)-N'-(4-(3-(N-metilcarbamoil)fenoxi)-fenil-urea y N - (3- tert -butylphenyl) - N ' - (4- (3- ( N- methylcarbamoyl) phenoxy) -phenyl-urea and N-(3-terc-butilfenil)-N'-(4-(4-acetilfenoxi)fenil-urea; N - (3- tert -butylphenyl) - N ' - (4- (4-acetylphenoxy) phenyl urea; las 5-terc-butil-2-metoxifenil-ureas:5- tert -butyl-2-methoxyphenyl ureas: N-(5-terc-butil-2-metoxifenil)-N'-(4-(1,3-dioxoisoindol-in-5-iloxi)fenil)-urea, N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (1,3-dioxoisoindole-in-5-yloxy) phenyl) -urea, N-(5-terc-butil-2-metoxifenil)-N'-(4-(1-oxoisoindolin-5-iloxi)fenil)-urea, N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (1-oxoisoindolin-5-yloxy) phenyl) -urea, N-(5-terc-butil-2-metoxifenil)-N'-(4-(4-metoxi-3-(N-metilcarbamoil)fenoxi)fenil)-urea y N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (4-methoxy-3- ( N- methylcarbamoyl) phenoxy) phenyl) -urea and N-(5-terc-butil-2-metoxifenil)-N'-(4-(3-(N-metilcarbamoil)fenoxi)fenil)-urea; N - (5- tert -butyl-2-methoxyphenyl) - N ' - (4- (3- ( N- methylcarbamoyl) phenoxy) phenyl) -urea; las 2-metoxi-5-trifluorometil)fenil-ureas:the 2-methoxy-5-trifluoromethyl) phenyl ureas: N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-(2-carbamoil-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3- (2-carbamoyl-4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-carbamoil-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2-carbamoyl-4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiltio)fenil)-urea, N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridylthio) phenyl) -urea, N-(2-metoxi-5-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(2-metoxi-5-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea; N - (2-methoxy-5- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea; las 4-cloro-3-(trifluorometil)fenil-ureas:the 4-Chloro-3- (trifluoromethyl) phenyl ureas: N-(4-cloro-3-(trifluorometil)fenil)-N'-(3-(2-carbamoil-4-piridiloxi)fenil)urea, N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N-(4-cloro-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-cloro-3-(trifluorometil)fenil)-N'-(4-(2-carbamoil-4-piridiloxi)fenil)-urea y N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) -urea and N-(4-cloro-3-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea; N - (4-Chloro-3- (trifluoromethyl) phenyl) - N '- (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea; las 4-bromo-3-(trifluorometil)fenil-ureas:the 4-Bromo-3- (trifluoromethyl) phenyl ureas: N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiltio)fenil)-urea, N - (4-Bromo-3- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridylthio) phenyl) -urea, N-(4-bromo-3-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (4-bromo-3- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(4-bromo-3-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea; y N - (4-bromo-3- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea; Y las 2-metoxi-4-cloro-5-(trifluorometil)fenil-ureas:the 2-methoxy-4-chloro-5- (trifluoromethyl) phenyl ureas: N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(3-(2-(N-metilcarbamoil)-4-piridiloxi)fenil)-urea, N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (3- (2- ( N- methylcarbamoyl) -4-pyridyloxy) phenyl) -urea, N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(4-(2-(N-metilcarbamoil)-4-piridiloxi)-fenil-urea, N - (2-Methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (4- (2- ( N- methylcarbamoyl) -4-pyridyloxy) -phenyl-urea, N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(2-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea y N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (2-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea and N-(2-metoxi-4-cloro-5-(trifluorometil)fenil)-N'-(3-cloro-4-(2-(N-metilcarbamoil)(4-piridiloxi))fenil)-urea. N - (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) - N ' - (3-chloro-4- (2- ( N- methylcarbamoyl) (4-pyridyloxy)) phenyl) -urea.
ES05028442T 1999-01-13 2000-01-12 USE OF DIFENIL-UREAS REPLACED WITH OMEGA-CARBOXIARILO AS INHIBITORS OF THE QUINASA RAF. Expired - Lifetime ES2272203T3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11587799P 1999-01-13 1999-01-13
US115877P 1999-01-13
US25726699A 1999-02-25 1999-02-25
US257266 1999-02-25
US42522899A 1999-10-22 1999-10-22
US425228 1999-10-22

Publications (2)

Publication Number Publication Date
ES2272203T1 true ES2272203T1 (en) 2007-05-01
ES2272203T3 ES2272203T3 (en) 2010-07-13

Family

ID=27381740

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05028442T Expired - Lifetime ES2272203T3 (en) 1999-01-13 2000-01-12 USE OF DIFENIL-UREAS REPLACED WITH OMEGA-CARBOXIARILO AS INHIBITORS OF THE QUINASA RAF.
ES00903239T Expired - Lifetime ES2255971T3 (en) 1999-01-13 2000-01-12 DIFENIL-UREAS REPLACED WITH OMEGA-CARBOXIARILO AS INHIBITORS OF THE QUINASA RAF.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00903239T Expired - Lifetime ES2255971T3 (en) 1999-01-13 2000-01-12 DIFENIL-UREAS REPLACED WITH OMEGA-CARBOXIARILO AS INHIBITORS OF THE QUINASA RAF.

Country Status (40)

Country Link
JP (2) JP3845792B2 (en)
KR (3) KR101091101B1 (en)
CN (2) CN1219764C (en)
AR (1) AR035310A1 (en)
AT (2) ATE321027T1 (en)
AU (1) AU2501600A (en)
BG (1) BG65945B1 (en)
BR (2) BRPI0007487B8 (en)
CA (1) CA2359510C (en)
CU (1) CU23213A3 (en)
CY (2) CY2200149T2 (en)
CZ (2) CZ302846B6 (en)
DE (4) DE60026822T2 (en)
DK (1) DK1140840T3 (en)
DZ (1) DZ3004A1 (en)
EE (1) EE04913B1 (en)
EG (1) EG24407A (en)
ES (2) ES2272203T3 (en)
GT (2) GT200000002AA (en)
HK (2) HK1045504B (en)
HR (1) HRP20010580B1 (en)
HU (2) HU225780B1 (en)
IL (2) IL144030A0 (en)
JO (1) JO2373B1 (en)
LU (1) LU91280I2 (en)
MA (1) MA26038A1 (en)
ME (1) MEP36908A (en)
MY (1) MY138897A (en)
NL (1) NL300242I2 (en)
NO (3) NO321059B1 (en)
NZ (1) NZ556598A (en)
PA (1) PA8489701A1 (en)
PL (1) PL215029B1 (en)
PT (2) PT1690853E (en)
RS (1) RS51497B (en)
SK (2) SK287419B6 (en)
SV (1) SV2001000004A (en)
TN (1) TNSN00010A1 (en)
TR (1) TR200102020T2 (en)
TW (1) TWI269791B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
PE20040522A1 (en) * 2002-05-29 2004-09-28 Novartis Ag DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
WO2005075425A2 (en) * 2004-01-30 2005-08-18 Merck Patent Gmbh Substituted bisarylurea derivatives as kinase inhibitors
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1797037B1 (en) * 2004-09-29 2014-12-17 Bayer HealthCare LLC Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
DE102005015253A1 (en) * 2005-04-04 2006-10-05 Merck Patent Gmbh New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets
CA2634084C (en) * 2005-12-21 2015-04-07 Roger Smith Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
CA2680398A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
EP2195286A2 (en) * 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
CN101372475B (en) * 2008-03-19 2012-01-04 南京工业大学 Aromatic heterocyclic substituted acardite derivative and use thereof
CN101298427B (en) * 2008-06-26 2012-03-21 中国科学院广州生物医药与健康研究院 Diaryl urea compound and use thereof
TW201012467A (en) 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
CN103254126A (en) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds
CN101362717B (en) * 2008-09-28 2013-02-06 四川大学 4-(4-amidoanilino)-2-(methylcarbamoyl) pyridine, derivates thereof and preparation, application thereof
JO3101B1 (en) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
CN102216280B (en) * 2009-01-22 2014-06-18 沈阳药科大学 Bisarylurea derivatives and their use
WO2011097526A1 (en) * 2010-02-05 2011-08-11 Irm Llc Compounds and compositions as protein kinase inhibitors
CN102219733A (en) * 2010-04-14 2011-10-19 上海医药工业研究院 Method for preparing sorafenib
CN101830847B (en) * 2010-05-18 2012-10-10 张南 Anticancer compound and preparation method thereof
CN102617458A (en) * 2010-05-18 2012-08-01 张南 Preparation method for anticancer compound
EP2621486A1 (en) * 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
JP2014505052A (en) * 2011-01-06 2014-02-27 ベータ ファルマ カナダ インコーポレーテッド New urea for cancer treatment and prevention
CN102875460A (en) * 2012-05-17 2013-01-16 上海奥博生物医药技术有限公司 Method for preparing sorafenib
CN103508961B (en) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 Antitumor drug
CN103408488A (en) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 Optimal synthetic method of sorafenib
CN103435553A (en) * 2013-09-16 2013-12-11 中国药科大学 Piperazine structure-based aryl formamide Raf kinase inhibitor and preparation method as well as application thereof
CN104672129B (en) * 2013-11-26 2019-06-25 广东东阳光药业有限公司 A kind of preparation method of carbamide compounds
CN104974132B (en) * 2014-04-08 2017-05-17 北大方正集团有限公司 Polysubstituted pyridine compound and preparation method and application thereof as well as pharmaceutical composition
CN104177292A (en) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 Method for industrial production of sorafenib tosylate polymorphic form I
CA2998647A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
CN105348186B (en) * 2015-10-15 2018-05-22 青岛海洋生物医药研究院股份有限公司 Deuterated substituted bisarylurea compound and preparation method thereof and the application in anti-tumor drug is prepared
CN105753841B (en) * 2016-01-18 2018-01-05 西安交通大学 A kind of N indazoles substituting thioureido analog derivative and its preparation method and application
CN105924390B (en) * 2016-05-19 2018-07-10 广州南新制药有限公司 A kind of synthetic method of Mei Tafeini
CN106699652B (en) * 2016-11-07 2020-11-13 天津大学 Sorafenib alpha-aminobutyrate and preparation method thereof
CN108264510A (en) 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 A kind of selective depression kinases compound and application thereof
CN107417604A (en) * 2017-07-25 2017-12-01 新发药业有限公司 Benzamide compound of 4 substituted pyridines 2 and preparation method and application
CN114025755A (en) * 2019-04-12 2022-02-08 台湾卫生研究院 Therapeutic use of heterocyclic compounds as kinase inhibitors
CN113831491B (en) * 2021-09-30 2023-03-24 南昌大学 Preparation method and adsorption application of pyrimidazole covalent organic framework

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973675A (en) * 1989-04-13 1990-11-27 University Of Tennessee Research Center Hybrid nitrosoureidoanthracyclines having antitumor activity
US5447987A (en) * 1993-12-24 1995-09-05 Shin-Etsu Chemical Co., Ltd. Organopolysiloxane compositions
WO1995033458A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
AU7585598A (en) * 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
EP1019040B1 (en) * 1997-05-23 2004-09-29 Bayer Corporation Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
AU9802198A (en) * 1997-10-21 1999-05-10 Pharmacia & Upjohn Company Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
DE69829412T2 (en) * 1997-12-22 2005-07-28 Bayer Pharmaceuticals Corp., West Haven INHIBITION OF RAF KINASE USING SYMMETRIC AND UNSYMMETRIC SUBSTITUTED UREAS

Also Published As

Publication number Publication date
HRP20010580B1 (en) 2010-07-31
PT1140840E (en) 2006-05-31
DE05028442T1 (en) 2007-02-22
IL144030A (en) 2010-06-30
TR200102020T2 (en) 2003-01-21
BRPI0017535B1 (en) 2018-02-14
JP4472669B2 (en) 2010-06-02
BR0007487A (en) 2003-09-23
CY2200149T2 (en) 2010-07-28
CZ299125B6 (en) 2008-04-30
MY138897A (en) 2009-08-28
DZ3004A1 (en) 2004-03-27
CN1721397A (en) 2006-01-18
IL144030A0 (en) 2002-04-21
JO2373B1 (en) 2006-12-12
DE60026822T2 (en) 2006-08-24
NL300242I1 (en) 2006-12-01
KR20010103738A (en) 2001-11-23
HU225780B1 (en) 2007-08-28
BG65945B1 (en) 2010-06-30
NO2007002I2 (en) 2009-10-05
SV2001000004A (en) 2001-01-10
NZ556598A (en) 2008-11-28
JP3845792B2 (en) 2006-11-15
BRPI0007487B8 (en) 2021-05-25
ATE321027T1 (en) 2006-04-15
MA26038A1 (en) 2004-04-01
NO20013463D0 (en) 2001-07-12
HK1087689A1 (en) 2006-10-20
CN100522934C (en) 2009-08-05
CA2359510A1 (en) 2000-07-20
HU230863B1 (en) 2018-10-29
ATE460398T1 (en) 2010-03-15
KR20110063595A (en) 2011-06-10
SK9882001A3 (en) 2002-04-04
HRP20010580A2 (en) 2002-08-31
TWI269791B (en) 2007-01-01
NO20013463L (en) 2001-09-12
AR035310A1 (en) 2004-05-12
RS51497B (en) 2011-04-30
CA2359510C (en) 2007-02-13
NO20055863L (en) 2001-09-12
YU49101A (en) 2004-05-12
PL360085A1 (en) 2004-09-06
NO321059B1 (en) 2006-03-06
DK1140840T3 (en) 2006-07-31
ES2255971T3 (en) 2006-07-16
EE200100368A (en) 2003-04-15
CY1110177T1 (en) 2015-01-14
MEP36908A (en) 2011-02-10
ES2272203T3 (en) 2010-07-13
BRPI0017535B8 (en) 2021-09-14
NL300242I2 (en) 2007-04-02
PL215029B1 (en) 2013-10-31
GT200000002AA (en) 2007-06-15
HK1045504A1 (en) 2002-11-29
GT200000002A (en) 2002-01-09
BG109688A (en) 2007-05-31
JP2006328075A (en) 2006-12-07
LU91280I9 (en) 2019-01-02
CN1219764C (en) 2005-09-21
KR101091101B1 (en) 2011-12-09
LU91280I2 (en) 2006-12-13
AU2501600A (en) 2000-08-01
CN1341098A (en) 2002-03-20
KR100719166B1 (en) 2007-05-17
DE122006000059I1 (en) 2007-02-15
PT1690853E (en) 2010-04-23
EG24407A (en) 2009-05-20
SK287419B6 (en) 2010-09-07
HU0600871D0 (en) 2007-01-29
CU23213A3 (en) 2007-06-20
HUP0300866A2 (en) 2003-07-28
HUP0300866A3 (en) 2006-04-28
DE60044004D1 (en) 2010-04-22
JP2003526613A (en) 2003-09-09
CZ302846B6 (en) 2011-12-14
HK1045504B (en) 2006-04-07
PA8489701A1 (en) 2002-11-18
KR20070020158A (en) 2007-02-16
DE60026822D1 (en) 2006-05-11
BRPI0007487B1 (en) 2015-07-07
NO2007002I1 (en) 2007-01-05
SK285532B6 (en) 2007-03-01
EE04913B1 (en) 2007-10-15
CZ20012489A3 (en) 2002-01-16
NO337326B1 (en) 2016-03-07
TNSN00010A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
ES2272203T1 (en) DIFENIL-UREAS REPLACED IN OMEGA POSITION WITH CARBOXIARILO AS INHIBITORS OF THE RAF QUINASA.
RU2001122818A (en) Urea derivatives (options), pharmaceutical composition (options) and method for treating a disease associated with the growth of cancer cells (options)
CO5570668A2 (en) HIMBACINE SUBSTITUTED TRICYCLES DERIVATIVES THAT ARE ANTAGONISTS OF THE THROMBINE RECEPTOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HRP20160967T1 (en) Heterocyclic compounds useful as pdk1 inhibitors
RU2403258C2 (en) Thiazolyldihydroindazoles
CY1107184T1 (en) TRICYCLE COMPETITORS THROMBIN RECEPTORS
EA200000110A1 (en) BICYCLIC BENZAMIDES DERIVATIVES OF 3- OR 4-SUBSTITUTED 4- (AMINOMETHIL) PIPERIDINE WITH GASTROKINETIC PROPERTIES
DK60887D0 (en) PIPERAZINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF ANTI-RHYTHMIC MEDICINAL PRODUCTS
CA2443950A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2003121236A (en) AILATED AMIDES OF FURAN- AND THIOPHENCARBOXYLIC ACIDS WITH LOCKING POTASSIUM CHANNEL ACTION
RU2012144751A (en) HETEROCYCLIC COMPOUNDS EFFECTIVE FOR KINASE INHIBITION
RU2003134544A (en) AMRIDES OF ANTRANILIC ACID, METHODS FOR PRODUCING THEM, THEIR APPLICATION AS ANTIARRHYTHMIC MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
RU2003119153A (en) ORTHO-, META-SUBSTITUTED BIS-Aryl COMPOUNDS, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200602060A1 (en) DERIVATIVES PYRROLIDIN-2-SHE AND PIPERIDIN-2-SHE USED AS INHIBITORS 11-BETA-HYDROXYSTEROID-DEGYDROGENASE
UY26750A1 (en) USEFUL THIOPHEN DERIVATIVES AS ANTI-TARGET AGENTS
NO327709B1 (en) 2&#39;-substituted 1,1&#39;-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them
AR036045A1 (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, ITS EMPLOYMENT FOR THE PREPARATION OF A MEDICINAL PRODUCT, AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR20150108879A (en) Pharmaceutical compositions comprising nitroxyl donors
RU2009136996A (en) TRICYCLIC COMPOUNDS THAT CAN BE USED FOR TREATING DISORDERS RELATED TO AN ABNORMAL IRON CONTENT OF THE ORGANISM
NO914960L (en) MEDICINE FOR CANCER THERAPY WITH ANTIHISTAMINE PROPERTIES
SK170999A3 (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
PE20221460A1 (en) 6-MEMBERED HETEROARYLAMINOSULFONAMIDES TO TREAT DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
ES534505A0 (en) A PROCEDURE FOR THE PREPARATION OF 1, 4-DIHYDROPYRIDINE COMPOUNDS
BR0215200A (en) Pyrrolidine-2-ones as xa factor inhibitors
RU2007141412A (en) Pyridyldimethylsulfonic Derivative